SC
MIST icon

Sapient Capital’s Milestone Pharmaceuticals MIST Stock Holding History

Sapient Capital’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,200
Closed -$24.8K – 430
2025
Q3 		$24.8K Buy
+12,200
New +$21.5K ﹤0.01% 386

Other funds holding MIST

PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Sapient Capital's MIST Position: Q4 2025 in Review

Sapient Capital sold out of Milestone Pharmaceuticals (MIST) in Q4 2025, closing a stake of 12,200 shares — an estimated $24.8K sold.

Sapient Capital first reported a position in MIST in Q3 2025 and held it in 1 quarter. The position peaked at $24.8K in Q3 2025. 79 funds tracked by Wall St. Rank hold MIST as of Q4 2025.

  • Sapient Capital reported no remaining Milestone Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Sapient Capital sold 12,200 Milestone Pharmaceuticals shares in Q4 2025, an estimated $24.8K.
  • Sapient Capital first reported a position in Milestone Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Sapient Capital's Milestone Pharmaceuticals position peaked at $24.8K in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2025.

Based on Sapient Capital's 13F filing for Q4 2025, filed 5 Feb 2026.